Baxter Boosts Profit Forecast Amid Strong Demand for IV Solutions
Baxter International raised its annual profit outlook, driven by strong sales of IV solutions, despite challenges in its infusion pump business.
Baxter International has revised its annual profit forecast upwards, attributing the boost to strong sales of its intravenous (IV) solutions. The Deerfield, Illinois-based medical products company announced the change after reporting quarterly results that surpassed Wall Street expectations.
Quarterly Performance Surpasses Expectations
Baxter's second-quarter revenue reached $2.96 billion, exceeding analysts' predictions of $2.80 billion, according to LSEG data. The company's largest segment, which includes IV solutions, saw a 7% increase in sales, totaling $2.08 billion. Baxter reported an adjusted profit of 56 cents per share, significantly higher than the anticipated 37 cents.
The robust performance in drug compounding and IV solutions has been a key driver of the company's improved financial outlook. However, this growth was partially offset by lower sales in infusion systems due to a continued hold on shipments and installations of its Novum infusion pump.
Challenges in Infusion Pump Business
Baxter is in the midst of a strategic turnaround, focusing on cost-cutting measures to address challenges in its infusion pump business. The company placed a hold on its Novum pump shipments and installations last quarter, a situation that is expected to persist throughout 2026 as customers await further updates on necessary corrections.
This hold has raised concerns among investors and analysts who are keenly observing whether the expiration of enhanced subsidies under the Affordable Care Act might affect elective procedure volumes and, consequently, the demand for surgical products.
Revised Profit Forecast
Despite these challenges, Baxter's revised annual profit forecast now ranges from $1.95 to $2.15 per share, up from the previous estimate of $1.85 to $2.05. This positive adjustment reflects the company's confidence in its core products and ongoing turnaround efforts.
The news of Baxter's improved outlook led to a 14% surge in its shares during premarket trading, signaling strong investor confidence in the company's future performance.
As Baxter continues to navigate its turnaround strategy, the focus remains on sustaining the growth of its medical products while addressing the issues within its infusion pump segment.